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Inflammation is a very complex immunopathological process occurring due to exaggerated activation
of immune system in response to various inflammatory stimuli (i.e. bacterial, viral, fungal or parasitic
antigens, xenobiotics, autoantigens and sterile inflammation of unknown cause (l.e. tumor associated
inflammation), traumatic inflammation or allergic inflammation etc.). Innate lymphoid cells (ILCs)
are particular newly discovered immune cells, which have characteristics of both innate and adaptive
immune cells. These cells have shown very significant roles in the pathogenesis of inflammatory disorders
at mucosal surfaces (i.e, respiratory tract, gastrointestinal tract and mucosal skin surfaces or barriers).
The present review, explores their role in pathogenesis of inflammation at mucosal sites.
Innate lymphoid cells (ILCs) are immune cells
which appear morphologically as lymphoid cells
but do not express specific antigen receptors (an
essential feature of adaptive immune cells) encoded
by rearranged genes (i.e. T-cell receptors (TCRs)
expressed by T cells). By origin, these cells represent
a heterogeneous group of hematopoietic innate
immune cells. ILCs differentiate from common
lymphoid progenitor (CLP) cells (Fig. 1) and
comprise a small fraction of the total immune cell
population in different lymphoid organs, at mucosal
epithelial barriers and in various other tissues.
Moreover, these cells are capable of producing
an array of effector cytokines which are similar to
helper T-cell cytokines. Thus, these cells include a
variety of cell types sharing common phenotypic
and functional characters (1, 2). However, mouse
models of infection and inflammation play a very
important role in identifying and classifying their
phenotypic characters and their functional diversity
(3-5). A recent study identified that in mouse fetal
liver and adult bone marrow cells expressing high
levels of PLZF, transcription factors act as common
precursors for ILCs and are known as ILCPs. These
ILCPs are further differentiated into ILC1, ILC2 and
ILC3 cells, however, NK cells and LTi cells do not
originate from these ILCPs (6). Experts in this field
have agreed that the term ILCs should be used to
encompass the lineage marker-negative (LIN-) ILCs,
.natural killer (NK) cells and lymphoid tissue-inducer
(LTi) cells (7). Therefore, it has been suggested that
ILCs can be further divided into three major groups:
i. Group 1 ILCs (comprised ofILCl and Nat-
ural Killer (NK) cells), include IFN-y producing
ILCs, expressing T-box transcription factor T-bet
and/or Eomes;
ii. Group 2 ILCs (ILCs 2) are GATA-binding
protein 3 (GATA3) and RORa-dependent ILCs,
which require these transcription factors for their
growth, development and function. These group 2
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Fig. 1. Postulated model for differentiation of ILCs and their postulated role in different immunologic conditions. For
example, Common lymphoid progenitor (CLP) in the presence ofIL- I5 leads to development ofNK cells, which secrete
IFN-y and have antiviral, and anti-tumor immune response. Whereas CLP lead to generation of innate lymphoid cell
progenitor (ILCP) and ILCPs are further differentiated into ILCI, ILC2 and ILC3 cells. ILCI also secrete IFN-y and
have role in antiviral immune response as well as against intracellular bacteria. ILC2 play important roles against
extracellular parasites as well as allergy (i.e. asthma) and influenza infection. ILC3 playa role in intestinal immune
response to pathogens (i.e. Citrobacter rodentium) as well as during autoimmunity like inflammatory bowel disease.
ILCP: Innate lymphoid cell progenitor; LN: Lymph Node; PPs: Payer sPatches; ILFs: Isolated Lymphoid Follicles.
ILCs secrete Th2 cytokines including IL-5 and IL-
13;
lll. Group 3 ILCs include RORyt+ ILCs and
lymphoid tissue inducer (LTi) cells, which can pro-
duce both IL-17 and IL-22 cytokines and, on the ba-
sis of expression of T-bet group 3 ILCs, can further
be categorized as following: (I) CCR6+T-bet group
3 ILC or (II) CCR6-T-bet+ group 3 ILCs.
A novel population of intraepithelial group I
ILCs has been reported, which are NKp44+CD I03+
cells and are characterized by the expression of
CD160, NKp46 and NKl.l (8). Significantly low
number of these group I ILCs have been observed
in mice lacking Nfi13 (also known as E4bp4) and
Tbx21 transcription factors. However, mice lacking
Il-15ra-l- did not show this defect (8). Thus, these
intraepithelial NKp46+NK 1.1+CD160+ ILC I cells are
distinct from conventional NK cells. The number of
these transepithelial group I ILCs was found to be
increased in anti-CD40-induced mOUSe models
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Table I. Summary of types, surface markers, location and functions of the different types of Il.Cs found in mice and
humans.
Group I ILCs NKp46'NK l.L'(strain CDI22'NKG2D' NK cells are dispersed in IFN,y by Antiviraland antitumor immuneresponse
NK cells and dependent)CD I22"NK CDI61'KIR' secondary lymphoid organs, blood n.cr by NK cells
G2' and peripheral organs. These cells cells IntraepitheliallLCI cells have protective
CDI61'CDI6'CDIlb' have role in tumorsurveillance, IFN-y, roleagainstenteropathogcns butaggravate
cytotoxic actionagainstvirus inflammatory bowel diseases
LINTDS6' infectedcells andamplificationof TNF-a (IBD)/Crohn's disease by secreting IFN-y
ILCI LIN-RORyt' NKp46' NKp30' an inflammatory immune and other
RORyt'm'(also NKp44'IL- 7Ra' response. cytotoxic
THYI'SCAI') IntraepitheliallLCs I have been effector
observed in GIT molecule
sbyNK
cells
Group 21LCs
ILC2s or LIN' LIN Adipose tissues of mouse IL-4,IL- Key role in antiparasitic
RORa- ICOS'SCAI'lW7Ra' ILn7Ra'CD4Sh' peritoneal cavity, in fatassociated 5,IL-9 (i.e.antihelminthic) immuneresponseand(RORaand dependent ILCs ST2"'(also THYI'IL- CDI61'CRTH2' lymphoid clusters (FALCs) of and IL- allergic lung inflammation (i.e. Asthma)GATA3-
dependent 17RB'CD2S') bothmouse andhuman 13 Wound healing
mesentery,mesentericlymph
ILCs)
node, gastrointestinal tract (GIT),
spleen. liver, Poyer's patches
(PPs), and respiratory tract (RT)
etc
Group31LCs ILC3s and LIN' LINCDS6"NKp4 Mucosaltissues. particularly in IL-22, Intestinal epithelial cell homeostasis.RORyt'NKp46'(also 6"NKp30"NKp4 intestinaltract(i.e. laminapropria IL-17 Immunity against intestinalbacteria,lSD,
(RORyflLCs) THY!'ILn7Ra;"KIT'" 4'ILn7Ra' (LP), PPs. mesenteric lymph controlof Candida albicans inducedCXCRS'CCR6') nodes, Palantinc tonsils, human fungal infection (i.e. Oropharyngeal
fetal lymph nodes. inflamed candidiasis)
humantonsils
LTi cells LIN RORyt"NKp46 LIN Mucosaltissues, particularly in LTa. Secondary lymphoid organ generation [i.e,
(also ILlI7RahiCD4S'" intestinaltract,fetal mouse LTp, IL- lymph nodes (LNs), Pcyer's patches (PPs)
THYI'IL;i7RahiKITh; RORyt'(alsoCD7 intestineand inflamedintestineof 17A, IL- and isolated lymphoid follicles (ILFs)],
CXCRS'CCR6'); a 'CDI6I'CD4- both mouse and humans,mouse 22 Intestinal homeostasis, Immunity against
proportion of LTi cells CD94 ) spleen andhumantonsils, mouse extracellular bacteria
arc CD4' intestinal cryptopatches (CPs)
of colitis and secreted higher levels of IFN-y
causing severe inflammatory tissue damage. Thus,
these group I ILCs may playa protective role against
enteropathogens but have a tendency to aggravate
inflammatory bowel disease (IBD)/Crohn's disease
(Fig. 1). Additionally, these transepithelia1 group
I NKp44+ CDI03+ ILCI also express T-bet and
Eomes transcription factors along with higher
levels of IKZF3 transcript as compared to other
ILCs. However, it is not possible to discuss every
aspect ofILCs in this manuscript so their major types
receptor expression, major cytokines secreted by
them and major role played by them are represented
in Table I.
Il.Cs in chronic respiratory tract inflammatory
disorders (i.e. Asthma)
Asthma isachronic inflammatory disorder oflower
respiratory tract and is characterized by the presence
of chronic lung inflammation, infiltration of lungs
with mast cells and eosinophils, hypersecretion ofthe
mucus, difficulty in breathing (bronchoconstriction).
According to one estimate, more than 300 million
people are affected with asthma throughout the world
(9). Various studies have shown that symptoms of
allergic asthma and lung inflammation develop
due to hyper activation of innate lymphoid cells,
as activation of these cells led to initiation of type-
2 immune response in respiratory tract (10-12).
These type 2 innate lymphoid cells (ILC2) in lungs
express ICaS (CD278), ST2, CD25 and CD44,
which require Id2 and CD127 (IL-7Ra) for their
development. Pathogenesis of fungal (i.e. Alternaria
alternate) aeroallergen induced allergic asthma is
also dependent on ILC2 cells. Additionally, mouse
model of papain induced pulmonary inflammation
also showed that the majority of Th2 cytokines (i.e.
IL-4, IL-5, IL-9 and IL-13) were produced by ILCs
despite the presence of fully developed Th2 cells.
IL-9 produced by ILCs also acts in a paracrine
manner and upregulates IL-5 and IL-13 production
by these cells (14). ILCs also play an important role
in Strongyloides venezuelensis infection-induced
lung eosinophilic inflammation (13). Infection
with S. venezuelensis or intranasal administration
of chitin leads to an increase in number of alveolar
epithelial type II cells (ATII cells) and IL-33 levels
(13). S. venezuelensis infection induces pulmonary
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accumulation of ILCs (13). Increased level of IL-
33 stimulates ILCs to produce higher levels of IL-5
and IL-13. This similar effect was also observed in
Rag2<-I-l mice, where infection with S. venezuelensis
increased the number ofATII cells, ILCs, eosinophils
and expression of IL-33 in lungs of infected mice.
This IL-33-mediated stimulation ofILCs in lungs led
to induction ofeosinophilic pulmonary inflammation
and helped in the expulsion of worms from lungs.
Similar findings have also been observed by Kamijo
et al. in protease allergen-associated allergic
pulmonary airway inflammation (14).
Recently, Kim et al. observed that obesity-
associated development of asthma is facilitated
by NLRP3 inflammasomes, IL-l p and IL-17
producing ILCs (15). These workers found that
airway hyperactivity associated with obesity was
also linked to an expansion of CCR6+ type 3 ILCs
producing IL-17A (ILC3 cells) in the lung. These
authors also found that a high fat diet (HFD) led
to release of IL-l p via stimulation of pulmonary
alveolar macrophages, which led to an expansion of
the number of pulmonary ILC3 cells. Blockade of
IL-lp with an IL-l receptor antagonist diminished
obesity-induced airway hyper reactivity (AHR) and
reduced the number ofILC3 cells. Thus, obesity may
be another factor for the exaggerated stimulation
of ILC3 cells and development of obesity-related
asthma.
IL-33-mediated stimulation ofILC2 cells involves
mTOR activation through p l l Od phosphoinositide
3-kinase (16). Blockade ofmTOR pathway inhibited
IL-33-induced IL-5 and IL-13 production by both
Th2 cells and ILC2s (16). Intranasal administration of
IL-33 induced airway inflammation in WT mice, and
adoptive transfer ofwild-type ILCs to IL-33 receptor-
deficient (St2-1-) mice recapitulated this inflammatory
and allergic immune response (16). However,
rapamycin (i.e. an mTOR inhibitor) treatment led
to inhibition of IL-33-dependent ILC, macrophage,
and eosinophil accumulation, cytokine secretion, and
exaggerated mucus secretion and its deposition in
airways. Hence, this study revealed an unrecognized
role of mTOR signaling in IL-33-stimulated, ILC-
dependent allergic airway inflammation in vivo,
which can be used as future therapeutic approach for
allergic airway inflammation.
Recently, presence ofNK as well as ILC2 cells in
the human lungs and peripheral blood ofboth healthy
subjects and patients suffering from asthma has been
identified (17). Pro-resolving ALXlFPR2 receptors
are expressed on both NK and ILC2 cells. Lipoxin
A4 (a natural pro-resolving ligand for ALXlFPR2)
induced an increased eosinophil apoptosis through
the activation ofNK cells and decreased production
of IL-13 from ILCs cells (17). Thus, inhibition of
activation of ILC2 via Lipoxin A4 and ALX/FPR2
receptors may prove beneficial in human cases
of asthma. Lower levels of Lipoxin A4 have been
observed in patients with severe asthma, which may
be the one of the several reasons for exaggerated
activation of ILC2 cells in this group of patients.
ILC22 cells secreting IL-22 in lungs exert an anti-
inflammatory effect during experimental allergic
asthma and inhibit acute hypersensitivity reaction
(AHR) and pulmonary inflammation. Besides in
asthma, group 2 ILCs also play a significant role
in the pathogenesis of chronic rhinosinusitis (CRS)
by releasing IL-13 in response to IL-33 released
through nasal epithelial cells (18). CRS is a chronic
inflammatory condition of the nasal and paranasal
sinus mucosa affecting more than 30 million people
annually (18).
ILCs in acute lung infection-associated pulmonary
inflammation
ILCs play an important role in influenza virus
infection of respiratory tract (19, 20). Chang et al.
showed that influenza A virus infection in mice led
to exaggerated production of IL-33 from alveolar
macrophages due to hyper activation of ILC2
cells via release of higher amounts of IL-13 (19),
whereas, Monticelli et al. showed that mouse ILCs
accumulated in lungs after influenza virus infection,
and their depletion led to loss of airway epithelial
integrity, diminished lung function and impaired
airway remodeling (20). However, administration of
amphiregulin (Arg) (a secretory product oflung ILC2
cells) abrogated these defects and led to restoration
of normal lung function and epithelial repair. Thus,
lung ILCs exhibit great potential in restoration of
airway epithelial integrity and tissue homeostasis
after infection with influenza virus (Fig. 2). These
studies show that ILCs play a very important role
in chronic as well as acute pulmonary inflammation
observed during allergic asthma and acute viral
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infections. However, their role in acute bacterial
infection, such as pneumonia or other chronic
inflammatory conditions of lungs like pulmonary
fibrosis or emphysema, remains to be defined.
ILCs, intestinal immune defense and inflammation
ILCs are present throughout the intestine and
play an important role in homeostasis of mucosal
immunity at intestinal mucosal barrier. For example,
cryptopatches (CPs) and isolated lymphoid follicles
(ILFs) are completely absent in mice which lack
NK.22 and LTi/LTi like cells due to absence of aryl
hydrocarbon receptor (Ahr, a transcription factor).
CPs are mucosal lymphoid organs of intestine
present in mice but are absent in human intestine,
which contain DCs common lymphoid progenitor
(Linckit'Il.Yku') cells, LTi-like cells as well as
small number of NKp46+ NK22 cells. Complete
absence of RORyt leads to severe loss of ILCs,
causing complete loss of all types of gut-associated
lymphoid tissues (GALT). Thus, ILCs are important
for normal homeostasis of mucosal immune system
of the intestine. Accumulation of human type 1 ILCs
(which secrete IFN-y) has been observed in inflamed
intestine of patients suffering from Crohn's disease
(CD) (21). Additionally, ILCs are also involved in the
generation of tertiary lymphoid tissue or organ (TLT
or TLO) in intestine under inflammatory conditions.
ILCs also play an important role in clearance of
intestinal parasites [i.e. Nipostringylus brasiliensis
(N brasiliensis)] (22) (Fig. 2). IL-25-1- mice
exhibited inefficient immune response required to
clear N brasiliensis and delayed cytokine production
by Th2 cells (23). IL-25 plays an important role in
regulation and activation of non-B/non-T (NBNT),
c-kit", FcepsilonRl- cells (NBNTc-Kit+IL-13+ cells),
which secrete various specific cytokines (i.e. IL-4-
, IL-5-, IL-13) (23). These cytokines are required
for regulation of Th2 differentiation, eosinophilia,
mastocytosis and hyperplasia of intestinal goblet
cells during helminth infection and their expulsion.
This newly identified cell population was
originally called 'nuocytes' reflecting their role as
primary cells required for IL-13 production (Nu is
the 13th letter of Greek alphabet). IL-25-1- animals are
deficient in 'nuocytes', which well correlates with
inefficient expulsion or clearance of N brasiliensis
by these animals. Administration of recombinant
IL-25 facilitates appearance and activation of
NBNTc-kit+IL-13+ cells (Nuocytes), leading to the
rapid removal of parasites (23). This increase in
number of nuocytes leading to their expansion can
easily be observed in spleen, mesenteric lymph
nodes, peritoneal cavity, lungs and blood upon IL-
25 cytokine immune challenge. These nuocytes can
be identified by expression of different cell surface
receptors (i.e. ICOS, Thy1.2, CCR9, IL-7Ra, IL-
17BR (IL-25BR), Tl/ST2 (IL-33R) and IL-2Ry
(CD132). In addition to these receptors, nuocytes
also express low levels of CCL3 (MIP-la), which
provides an answer for observed neutrophilia in
mice treated with recombinant IL-25 (rIL-25). In
the presence of both IL-17 and IL-33 these nuocytes
rapidly proliferate and maintain their healthy state
for up to 6 days in vitro, thus both IL-17 and IL-33
are required for proper function of these nuocytes.
However, in the presence of IL-33 these cells also
produce IL-6, IL-IO and GM-CSF cytokines along
with IL-5 and IL-13.
These ILCs also play an important role in immune
defense against intestinal bacterial infection. For
example, RORyt+ ILCs play an important role in
defense against Citrobacter rodentium (24, 25).
During Citrobacter rodentium infection CD4+
LTi cells act as dominant source of early IL-22
release and this response is dependent on IL-23 as
ablation of IL-23 impairs the innate immunity (25).
Additionally, depletion of CD4+ LTi cells abrogates
infection-induced expression of IL-22 and anti-
microbial peptides (AMPs), causing an increase in
mortality of infected animals. LTi cells are important
for host to provide full protective immunity against
bacterial infection (Fig. 2). This early release of IL-
22 by intestinal ILCs is induced by lymphotoxin (LT)
during Citrobacter rodentium infection (25). Besides
playing an important role in bacterial infection
these cells are also important for symbiotic bacteria
residing at mucosal surfaces (26).
ILCs regulate selective containment oflymphoid-
resident bacteria to prevent systemic inflammation
associated with chronic diseases (27). Depletion of
intestinal IL-22-producing ILCs caused peripheral
dissemination of commensal gut bacteria and
initiated the systemic inflammatory response or
sepsis (27) (Fig. 2). Administration of IL-22 led to
inhibition of this severe systemic inflammation and
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Fig. 2. Role ofILCs in different inflammatory conditions ofrespiratory tract (i.e. lungs, upper respiratory tract), intestine
and skin barrier. For example. parasitic infections, or bacterial infections or viral infection (i.e. influenza virus infection
of lungs) as well as allergens (i.e. MC903) lead to activation of Th2 immune response activation via the activation of
group 2 ILCs present in lungs, nasal epithelium, intestine and skin, causing associated inflammatory disorders. Release
ofTSLPfrom skin epithelial cells causes activation ofILC2 cells, which causes exaggerated skin inflammation and atopic
dermatitis-like conditions. and ILCs play an important role in psoriasiform plaque formation.
peripheral dissemination of bacteria. According to
these authors, these disseminating bacteria belong
to Alcaligenes species, which originate from host
lymphoid tissues. These Alcaligenes were sufficient
to promote systemic inflammation in mice depleted
of ILCs. Alcaligenes-specific systemic immune
response was associated with CD and progressive
hepatitis C virus infection in patients as presence of
Alcaligenes-specific antibody in serum of patients
suffering from CD and chronically hepatitis-C
virus infected individuals was confirmed (27). Mice
deficient in RORyt+ ILCs develop severe form of
dextran sodium sulphate (DSS)-induced colitis with
severe systemic dissemination ofcommensal bacteria
and inflammation is mediated by IgG antibody
leading to development of systemic inflammation,
while WT mice exhibit only colon specific contained
colitis without any systemic inflammation.
IL-22 produced by ILCs in intestine has protective
action against IBD and provides host defense against
pathogens (28). Thus, identification ofILC-mediated
pathway for limiting and controlling the containment
and prevention of dissemination of Alcaligenes
can prove beneficial in terms of designing new
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therapeutic approach targeting ILCs to limit the
systemic inflammation associated with this bacteria
during various pathologic conditions (i.e. AIDS, CD,
HCV associated hepatitis, Cystic fibrosis (CF) and
Cancer etc.). ILC17 restricted to mucosal tissues
were significantly lost in the jejunum during simian
immunodeficiency virus (SIV) infection (29). These
results indicate that loss of innate immune function
mediated by ILC17 cells at mucosal surfaces may
lead to disruption of intestinal mucosal immune
system integrity and progression of HIV infection in
humans or SIV infection in macaques.
Recent findings have shown that both bacteria-
induced colitis and colon cancer are accompanied
by accumulation of IL-17+IL-22+ colonic innate
lymphoid cells (cILCs), and depletion of these cells
from colon in mice leads to blockage ofdevelopment
of invasive colonic cancer (30). Guo et al. identified
that STAT3 inhibition during cancer chemotherapy,
inhibits production of IL-22 by ILC3 cells and
makes host more prone to develop bacterial infection
(i.e. Citrobatcer rodentium in mice), diarrhea and
associated mortality (31). Citrobacter rodentium
is a natural mouse extracellular enteric pathogen
that mimics human enterohaemorrhagic E. coli and
enteropathogenic E. coli, which are responsible
for major causes of diarrheal diseases associated
with several thousand deaths of individuals
worldwide every year. These authors observed that
administration of IL-22 was sufficient to rescue the
STAT3 deficient animals from developing severe
intestinal bacterial infection, associated diarrhea and
mortality. A recent study by Spencer et al. has shown
that vitamin A deficiency led to severe deficiency
of group 3 ILCs in intestine and upregulated the
frequency of number of group 2 ILC populations
(32). This further decreased the level of IL-17 and
IL-22 production but increased the production ofIL-
4, IL-5 and IL-13 (32). Further inhibition of vitamin
A signaling by vitamin A metabolite retinoic acid
also caused decrease in the number of ILC3s and an
increase in the number of ILC2 cells in both wild
type (WT) and immunocompromised mice. Thus,
retinoic acid controlled the balance of these two ILC
subsets in mouse intestine. These vitamin A-deficient
mice were more prone to develop bacterial infection
(i.e. Citrobacter rodentium) due to deficiency of
ILC3s in their intestine. Both vitamin A-deficient
,
and retinoic acid inhibitor-treated mice exhibited
enhanced protection against infection with Trichuris
muris. This enhanced protection was supposed to
be associated with an increased frequency of IL-13-
producing ILC2s and was independent of adaptive
immunity. Furthermore, as type 2 immunity is
associated with tissue repair and increased mucus
production, this may improve intestinal mucosal
barrier integrity.
lLCs at mucosal, skin barriers and associated
inflammatory disorders and regeneration .
Sterile inflammation resulting in the absence of
infection due to metabolic or exogenous sources
induced stimulation of innate immune system also
proves detrimental to host. These ILCs have also
been implicated in the initiation of psoriasiform
plaque formation in mice and gut microbial
associated intestinal inflammation (33, 34). Kim
et al. identified the presence of group 2 ILCs in
human skin of healthy individuals and found the
number of these cells increases in the skin lesions of
persons suffering from atopic dermatitis (35). These
workers also found the presence of these cells in
mouse skin and that they played an important role
in the development of atopic dermatitis-like skin
disease in these animals. However, according to
them, group 2 ILCs present in skin and skin draining
lymph nodes play an inflammatory role independent
of IL-33 and IL-25-mediated cytokine signaling
required for intestinal and pulmonary group 2 ILCs.
Instead, their inflammatory role in skin lesions of
atopic dermatitis patients was dependent on thymic
stromal lymphopoietin (TSLP). A recent study also
confirmed this finding and showed that ILC2 cells are
present in mouse skin and promote atopic-dermatitis
(AD)-like inflammatory immune response (36). LTi
cells also play an important role in regeneration of
thymus insulted by endogenous cytokine, IL-23.
Regeneration ofthymus was induced by upregulation
of LTi function through IL-22 administration (37).
Thus, ILCs also play an important role in resolution
of sterile inflammation and regeneration.
lLCs in oral mucosal barrier infections and various
other mucosal sites
Additionally, a recent study showed that during
Candida albicans infection, ILC17 play an important
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role in the control of fungal infection (38). In mouse
model of oropharyngeal candidiasis, IL-17A and
IL-17F (both cytokines are important for pathogen
clearance) are produced promptly during the course
of infection in an IL-23-dependent manner. ILCs in
oral mucosa are the main source for these cytokines
as Ab-mediated depletion ofILCs in RAG l-deficient
mice or ILC deficiency in retinoic acid-related
orphan receptor c(-/-) mice led to complete failure of
control ofCandida albicans infection (38). Thus, IL-
17-secreting ILCs (i.e. ILC 17) play an important role
in host defense against fungal infection at mucosal
surfaces. However, ILC 17 in mice lack expression
ofNCR NKp46 and also are CD4'CD 117', indicating
that these ILC 17 are different from NKp46+ ILC22
or IL-22 producing cells or CD4+CD117+ LTi cells.
Furthermore, a role of Thy-l + ILCs has also
been identified during choroidal neovascularization
(CNV), which is the hallmark of wet age-related
macular degeneration (AMD) (39). AMD is the
leading cause of irreversible visual damage observed
in patients 60 years of age or over in the Western
world. During their study, the authors found that IL-17
had a great potential for inducing neovascularization
in a vascular endothelial growth factor (VEGF)-
independent manner in laser-induced experimental
CNV in mice. yoT cells and Thy-l +ILCs were the
major source of pro-inflammatory cytokine IL-17
in injured eyes causing the development of CNY.
Thus, ILCs are emerging as major immune cells
playing a role in the pathogenesis of inflammatory
damage at different mucosal surfaces (i.e. RT,
GIT, nasal mucosal tissues, skin and oral mucosa
etc.). In a recent study Mair and Becher found
increased infiltration of Thy-l "Sea1+ ILCs in the
mouse model of autoimmune CNS inflammation
[i.e. Experimental autoimmune encephalitis (EAE)]
(40). These Thy-l 'Scal ' ILCs were characterized
by the expression of IL-7 receptor and secretion of
IL-17 and IFN-y. However, upon specific depletion
of this cell population in mice these workers found
that infiltration of these Thy-l"Sea I+ ILCs into
the CNS did not have any impact on the course of
autoimmune CNS inflammation (i.e. EAE) in their
mouse model. Thus, further studies focused on ILCs
and pathogenesis of brain inflammation are required
to establish their active role in inflammatory brain
disorders.
Future perspective
These ILCs are relatively newer immunological
cells and their function in terms ofintestinal lymphoid
tissue generation, and tissue remodeling as well as
their pathogenic contribution to different human
inflammatory disorders (i.e. CD or inflammatory
bowel diseases (IBD), colon cancer, lung Cancer
etc.) needs to be studied in detail. A recent study by
Kruglov et al. showed that soluble lymphotoxin U
(sLTu3) produced by RORyt+ innate lymphoid cells
(ILCs) controls induction of T-cell-dependent IgA
production in the lamina propria via regulation of
T cells homing to the gut (41). While, membrane-
bound lymphotoxin p(LTu,P2) produced by RORyt+
ILCs plays an important role in induction of T-cell-
independent IgA production in the lamina propria via
control of dendritic cell functions (41). Depletion of
LTu in RORyt+ cells ceased IgA production in gut
and led to change in intestinal microflora of mice.
Thus, soluble and membrane-bound lymphotoxins
produced by ILCs have property to organize the gut
adaptive immunity through distinct mechanisms and
also control the host intestinal commensal microbiota
diversity and composition.
Amphiregulin (Areg), a secretory product of
lung ILC2 has been reported to restore normal
lung function and epithelial repair during influenza
virus infection-associated pulmonary inflammation.
Future. studies to identify the role of Areg during
IBD or CD may prove beneficial to restore intestinal
epithelial cell integrity and normal intestinal function
in patients suffering from intestinal inflammatory
disorder. Since Th2 immune response is also
associated with llergic immune responses and both
ILC2 cells and Th2 cells require GATA3 for their
growth, development and function, an interaction
between these two cells types during pathogenesis
of type 2 allergic immune responses associated with
asthma or parasitic infection may prove beneficial
to understand the exact pathophysiology of these
diseases. For example, it has been observed that ILC2
cells produce more IL-5 and IL-13 upon stimulation
with IL-33 in combination with IL-2, IL-7 or TSLP
as compared to Th2 cells. Based on current available
data, ILC2 cells function at a very early phase of
immune response during type 2 allergic immune
response (i.e. asthma or during parasitic infection)
when naive CD4 T cells differentiate into Th2 cells or
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ILC2 cells have tendency to synergize the effector or
pathogenic memory Th2 cells to induce or exaggerate
the inflammatory process. Hence, it has become
very important to define phenotypic and functional
differences between pathogenic memory Th2 cells
and IL-5 and IL-13 producing group 2 ILCs and their
impact on type 2 allergic inflammatory disorders.
Future studies targeting different approaches towards
mechanism of infiltration of different ILCs at the
site of mucosal inflammation and their interaction
with different innate (i.e. neutrophils, macrophages,
mast cells etc.) and adaptive immune cells [various
kinds of T cells (i.e. cytotoxic T cells, helper T cells
and regulatory T cells etc.) and B cells] will prove
beneficial in designing a new therapeutic approach to
inflammatory disorders of mucosal tissues.
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